Table 3.
Multivariate analysis for long-term all-cause mortality
| Univariate | Multivariate | |||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| LOY >17% | 2.195. (1.444–3.337) | 0.000 | 2.079 (1.362–3.173) | 0.001 |
| EuroSCORE II | 1.042 (1.021–1.063) | 0.000 | 1.022 (0.992–1.050) | 0.151 |
| eGFR (mL/min/1.73 m2) | 0.981 (0.971–0.991) | 0.000 | 0.982 (0.973–0.992) | 0.001 |
| NYHA class | 1.974 (1.317–2.959) | 0.001 | 1.656 (1.107–2.478) | 0.014 |
| Anemia | 2.294 (1.059–4.965) | 0.035 | 2.942 (1.804–4.797) | 0.000 |
| Previous PCI | 0.602 (0.358–1.011) | 0.055 | 0.680 (0.404–1.145) | 0.147 |
| CAD | 1.221 (0.989–1.506) | 0.063 | 1.092 (0.914–1.304) | 0.331 |
| Hypertension | 0.639 (0.390–1.049) | 0.076 | 0.612 (0.376–0.998) | 0.049 |
| Age | 1.033 (0.994–1.074) | 0.099 | 1.004 (0.970–1.039) | 0.835 |
| PPM | 1.537 (0.911–2.592) | 0.107 | ||
| AF | 1.369 (0.883–2.122) | 0.160 | ||
| BMI | 0.964 (0.915–1.016) | 0.170 | ||
| COPD | 1.360 (0.824–2.245) | 0.229 | ||
| Previous TIA | 0.530 (0.128–2.189) | 0.380 | ||
| Previous stroke | 1.222 (0.654–2.281) | 0.530 | ||
| CVD | 0.846 (0.498–1.436) | 0.536 | ||
| Platelets (/nL) | 0.999 (0.996–1.002) | 0.536 | ||
| Leukocytes (/n) | 1.018 (0.948–1.094) | 0.617 | ||
| Hematocrit (%) | 0.959 (0.895–1.028) | 0.240 | ||
| PAOD | 0.885 (0.470–1.665) | 0.704 | ||
| Previous MI | 1.086 (0.631–1.869) | 0.765 | ||
| Diabetes | 0.964 (0.611–1.521) | 0.875 | ||
AF, atrial fibrillation; BMI, body mass index; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; MI, myocardial infarction; NYHA, New York Heart Association; PAOD, peripheral arterial occlusive disease; PCI, percutaneous coronary intervention; PPM, permanent pacemaker implantation; TIA, transient ischemic attack.
Anemia was defined according to WHO criteria as < 13 g/dL in male patients and < 12 g/dL in female patients. Loss of Y chromosome (Y/X) ratio and anemia were used as dichotomised variables. Age, Euroscore II and laboratory parameters were used as continuous variables. All clinically relevant variables and laboratory parameters were included in univariate analyses, except those already included in EuroSCORE II (i.e. sex, left ventricular ejection fraction) to avoid dual inclusion. For multivariate analysis, those covariables reaching a P-value <0.1 in univariate analyses were included.